SBIR-STTR Award

Improving the Design of CRISPR/Cas9 Knockout Assays
Award last edited on: 4/6/2018

Sponsored Program
STTR
Awarding Agency
NIH : NIGMS
Total Award Amount
$223,896
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Xiaowei Wang

Company Information

Nawgen LLC

4320 Forest Park Avenue Suite 303
Saint Louis, MO 63108
   (314) 485-9642
   info@nawgen.com
   www.nawgen.com

Research Institution

----------

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2018
Phase I Amount
$223,896
The CRISPR/Cas9 system has been developed in recent years for genome editing, and it has been rapidly and widely adopted by the scientific community. The main objective of this grant application is to develop next-generation single guide RNA (sgRNA), which is a critical component for CRISPR/Cas9 knockout assays. The sgRNA determines both the efficacy and specificity of CRISPR/Cas9 editing activities. However, the efficacy of sgRNA has not been adequately considered previously. The design of potent sgRNAs is highly desired, as inefficient genome editing by CRISPR/Cas9 will inevitably lead to significant waste of resources at the experimental validation stage. To address this challenge, we have developed both bioinformatics and experimental methods for improving the design of sgRNAs with high potency and specificity. Based on these newly established methods, we propose to further develop a new sgRNA design method to significantly improve the potency of CRIPSR/Cas9 knockout assays. Our new genome-wide sgRNA assays will lay a solid foundation for further commercial development of CRISPR/Cas9 products that can be used in a variety of gene knockout applications, such as the analysis of individual gene function, high-throughput functional screen and gene therapy.

Public Health Relevance Statement:
RELEVANCE The CRISPR/Cas9 system has been developed in recent years for genome editing, and it has been rapidly and widely adopted by the scientific community. The main objective of this grant application is to develop next-generation single guide RNA (sgRNA), which is a critical component for CRISPR/Cas9 knockout assays. Our new genome-wide sgRNA assays will lay a solid foundation for further commercial development of CRISPR/Cas9 products that can be used in a variety of gene knockout applications, such as the analysis of individual gene function, high-throughput functional screen and gene therapy.

Project Terms:
Address; Adopted; Applications Grants; Bacteria; base; Bioinformatics; Biological Assay; biological research; Chimera organism; clinical application; Clustered Regularly Interspaced Short Palindromic Repeats; Communities; CRISPR/Cas technology; Data; Databases; design; Development; Engineering; Foundations; gene function; gene therapy; Genome; genome editing; genome-wide; Goals; Guide RNA; improved; Individual; Knock-out; knockout gene; Lead; Libraries; Methods; next generation; Performance; Proteins; Research Infrastructure; Resources; RNA; RNA Databases; scaffold; Services; Site; Solid; Specificity; System; Validation; wasting; Work

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
----
Phase II Amount
----